Oramed Pharmaceuticals Inc. (ORMP)
Chart Events
Performance Outlook
| Previous Close | 4.85 |
| Open | 4.83 |
| Bid | 5.08 x 800 |
| Ask | 5.08 x 2200 |
| Day's Range | 4.88 - 5.25 |
| 52 Week Range | 3.59 - 31.54 |
| Volume | |
| Avg. Volume | 830,500 |
| Market Cap | 195.519M |
| Beta (5Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ORMP
Related Research
- Oramed Pharmaceuticals Inc.Technical Assessment: Bearish in the Intermediate-TermMarket sentiment remains in the tank and the stock market simply cannot put together a decent rally. The National Association of Active Investment Managers (NAAIM) exposure index has fallen back to 20%, an extremely low equity exposure and a very bearish stance toward equities. This is the second time the index has dropped to 20% in the past six weeks. The seven-week average of exposure has fallen to 30%, the lowest since the pandemic low, as well as in 2015, 2011, and 2008/2009.RatingFair ValueEconomic Moat6 days agoArgus Research
- PR Newswire
Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.
- PR Newswire
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-lik
- PR Newswire
Oramed to Present at H.C. Wainwright Global Investment Conference
Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview at the H.C. Wainwright Global Investment Conference, on May 25, 2022 in Miami, Florida.
